These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 31648470)

  • 21. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia.
    Shen X; Pan J; Qi C; Feng Y; Wu H; Qian S; Lu H; Chen L; Li J; Miao K; Qiu H; Zhu H
    Hematology; 2021 Dec; 26(1):295-300. PubMed ID: 33648437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT.
    Xuan L; Fan Z; Zhang Y; Zhou H; Huang F; Dai M; Nie D; Lin D; Xu N; Guo X; Jiang Q; Sun J; Xiao Y; Liu Q
    Oncotarget; 2016 May; 7(22):32579-91. PubMed ID: 27081039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
    Wang Z; Yin C; Zhang W; Tang W; Song X; Hu X; Ni X; Qiu H; Yang J; Hu J; Wang J
    Ann Hematol; 2019 Jul; 98(7):1765-1773. PubMed ID: 30993416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
    Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
    Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Tan Y; Du K; Luo Y; Shi J; Cao L; Zheng Y; Zheng G; Zhao Y; Ye X; Cai Z; Huang H
    Transfusion; 2014 Jun; 54(6):1493-500. PubMed ID: 24372162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis.
    Fan S; Pan TZ; Dou LP; Zhao YM; Zhang XH; Xu LP; Wang Y; Huang XJ; Mo XD
    Front Immunol; 2023; 14():1091014. PubMed ID: 36817493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of Donor Lymphocyte Infusion for Treating Relapsed High-Risk Leukemia patients after Allogeneic Hematopoietic Stem Cell Transplantation].
    Wang YX; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):982-8. PubMed ID: 26314430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study.
    Zhang R; Wang L; Chen P; Gao X; Wang S; Li F; Dou L; Gao C; Li Y; Liu D
    Cancer Med; 2021 May; 10(10):3165-3176. PubMed ID: 33932107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
    Terwey TH; Le Duc TM; Hemmati PG; le Coutre P; Nagy M; Martus P; Dörken B; Arnold R
    Ann Oncol; 2013 May; 24(5):1363-70. PubMed ID: 23247660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of venetoclax combined with decitabine, modified HA regimen and DLI in the treatment of relapsed pediatric AML/MDS after allogeneic hematopoietic stem cell transplantation].
    Zhang F; Wang HF; Hu GH; Suo P; Bai L; Wang Y; Zhang XH; Huang XJ; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):832-837. PubMed ID: 39414606
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].
    Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS
    Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
    Schmid C; Labopin M; Schaap N; Veelken H; Brecht A; Stadler M; Finke J; Baron F; Collin M; Bug G; Ljungman P; Blaise D; Tischer J; Bloor A; Kulagin A; Giebel S; Gorin NC; Esteve J; Ciceri F; Savani B; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Feb; 57(2):215-223. PubMed ID: 34750562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation.
    Gröger M; Gagelmann N; Wolschke C; von Pein UM; Klyuchnikov E; Christopeit M; Zander A; Ayuk F; Kröger N
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1399-1405. PubMed ID: 29684563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment.
    Yan CH; Wang Y; Sun YQ; Cheng YF; Mo XD; Wang FR; Chen YH; Zhang YY; Han TT; Chen H; Xu LP; Zhang XH; Liu KY; Huang XJ
    Cancer Commun (Lond); 2022 Dec; 42(12):1387-1402. PubMed ID: 36274263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.